[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IRCCS Sacro Cuore Don Calabria di Negrar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":272},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,64,92,113,136,163,185,208,229,252],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100634310","pilot-randomized-study-for-treatment-volume-de-escalation-for-spinal-metastases-with-stereotactic-body-radiation-therapy-100634310",false,"NCT07538024","Pilot Randomized Study for Treatment Volume De-Escalation for Spinal Metastases With Stereotactic Body Radiation Therapy","A Randomized, Pilot Study on tREatment VOLume De-escalation for SPINal mEtastases SBRT (REVOL-SPINE)","REVOL-SPINE","Inclusion Criteria:\n\n* Patients affected by spinal metastases eligible for SBRT\n* All histologies are allowed\n* Oligometastatic disease (maximum 5 metastases) in every setting (oligopersistent, oligorecurrent and oligoprogressive, according to ESTRO consensus)\n* Metastases treated with ablative intent\n* Both symptomatic and asymptomatic vertebral metastases\n* Spine Instability Neoplastic Score (SINS) score \\\u003C 7 \\[18\\]\n* Age \\> 18 years\n* Life expectancy \\> 12 months\n* PS ECOG 0-1\n* Vertebral pathological lesion on the diagnostic MRI\n* Single active lesion on the target vertebra\n* More lesions in different vertebrae can be simultaneously treated\n* Informed consent to trial participation and personal data treatment\n\nExclusion Criteria:\n\n* More than 2 adjoining vertebrae involved\n* Palliative intent\n* 2 or more lesions on the target vertebra\n* Contraindications to MRI\n* More than 5 metastases","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","A single centre, non-profit, randomised, unblinded pilot study on volume definition for spinal stereotactic body radiation therapy treatment.\n\nRandomization will be 1:1 between two types of SBRT treatment for spinal metastases. The statistical unit will be the individual vertebral metastasis. Multiple metastases will be randomized and evaluated independently.",[27],"Metastases to Bone","RECRUITING","2026-04-10",{"date":31,"type":32},"2026-04-20","ACTUAL",{"date":34,"type":32},"2025-11-04",{"date":36,"type":21},"2029-05-04",{"name":38,"class":39},"IRCCS Sacro Cuore Don Calabria di Negrar","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100630425","evaluation-and-assessment-for-communicable-diseases-in-migrants-hosted-in-reception-centers-100630425","NCT07487506","Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Centers","REACH - Responsive Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Centers","REACH","Inclusion Criteria:\n\n* All asylum seekers residing in reception centers who are 18 years of age or older, have been in Italy for at least 2 months but no more than 36 months, who express their consent to undergo screening.\n\nExclusion Criteria:\n\n* Individuals under the age of 18; Asylum seekers who have been in Italy for less than 2 months or for more than 36 months; Refusal to consent to participate in the study",true,{"count":51,"type":21},250,[24],"A single-centre, non-profit experimental clinical trial. The aim of the study is to estimate the prevalence of a range of infections and infectious diseases in a cohort of asylum seekers staying in initial reception centres, who have been in Italy for at least 2 months but no more than 36 months. The infections of interest are: latent tuberculosis and active tuberculosis, HIV, HBV, HCV, syphilis, strongyloidiasis, schistosomiasis, filariasis, and intestinal helminthiasis.",[55],"Infections","2026-03-24",{"date":58,"type":32},"2026-03-30",{"date":60,"type":32},"2025-04-08",{"date":62,"type":21},"2026-09-08",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100630175","matching---female-genital-schistosomiasis-in-migrants-female-genital-schistosomiasis-in-migrants-presenting-to-an-outpatient-clinic-in-italy-prevalence-and-clinical-impact-100630175","NCT07484256","MATCHING - feMAle geniTal sCHistosomiasis IN miGrants Female Genital Schistosomiasis in Migrants Presenting to an Outpatient Clinic in Italy: Prevalence and Clinical Impact","MATCHING","Inclusion Criteria:\n\n* childbearing age (15-49 years);\n* origin from Schistosoma -endemic country;\n* presence of at least one of the following symptoms compatible with FGS: abnormal vaginal discharge, vaginal spotting\u002Fbleeding, genital itching or burning sensation, pelvic pain\u002Fdyspareunia, genital ulcers, macrohematuria, subfertility\u002Finfertility, miscarriage and\u002For extrauterine pregnancy, unexplained anemia, menstrual irregularities, previous birth of a premature\u002Flow birth weight fetus or growth retarded baby;\n* Informed consent to study participation and to personal data's treatment.\n\nExclusion Criteria:\n\n* Deny of informed consent to study participation.","FEMALE","15 Years","49 Years",{"count":75,"type":21},96,[24],"The aim of this study is to evaluate the prevalence of female genital schistosomiasis (FGS) in the migrant population with gynecological problems who access our center's dedicated outpatient clinic. Furthermore, we will address the relevance of FGS in women with clinical manifestations of the upper genital tract and evaluate the role of cervical-vaginal swabs in predicting upper genital tract involvement in schistosomiasis infection.\n\nThe study is classified as experimental despite its descriptive objective of the prevalence of the infection of interest, as the vaginal swab and the PCR test performed on the swab and, if necessary, on the histological sample (collected during a possible interventional procedure performed for the patient's clinical needs) are not part of the standard clinical management of these cases but will be performed for the purposes of the study.",[79],"Female Genital Schistosomiasis",[81,82,83],"female","genital","schistosomiasis","2026-03-16",{"date":86,"type":32},"2026-03-20",{"date":88,"type":32},"2025-02-20",{"date":90,"type":21},"2027-08",{"name":38,"class":39},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":40},"100584643","observational-study-on-viral-shedding-and-immunological-response-of-oropouche-virus-100584643","NCT06892015","OBSERVATIONAL STUDY ON VIRAL SHEDDING AND IMMUNOLOGICAL RESPONSE OF OROPOUCHE VIRUS","OROVIMM","Inclusion Criteria:\n\n* patients resulted positive to the RT-PCR for OROV;\n* informed consent to the participation to the study and to personal data's treatment and\u002For donation of residual samples to Tropika Biobank;\n* patients ≥ 18 years old.\n\nExclusion Criteria\n\n• lack of signed informed consent.",{"count":100,"type":21},30,"OBSERVATIONAL","This is a single-center observational study, whose primary objective is to describe the immune response to Oropouche Virus (OROV) during the study period and the duration of viral RNA shedding, only for sequential samples, by RT-PCR in different matrices.",[104],"Oropouche Infection","2025-05-16",{"date":107,"type":32},"2025-05-18",{"date":109,"type":32},"2024-12-19",{"date":111,"type":21},"2026-10",{"name":38,"class":39},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":49,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100575777","characterisation-of-dengue-vaccine-induced-specific-immunity-in-vaccinees-with-and-without-prior-exposure-to-flavivirus-infections-or-vaccination-100575777","NCT06776692","Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","Characterisation of Dengue Vaccine (Qdenga®, TAK-003)-Induced Humoral and Cellular Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","VaQDENV","Inclusion Criteria:\n\n* Subjects of both sexes presenting to the DITM to receive the anti-DENV vaccine whether or not they have had a history of prior DENV or other flaviviruses infection or a history of prior vaccination against other flaviviruses. These data will be recorded in the study CRF.\n* Age \\>= 4 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 4 years.\n* Absence of signed informed consent.","4 Years",{"count":123,"type":21},402,"The goal of this observational study is to learn about the immunity induced by the Qdenga® vaccine in vaccinees.\n\nParticipants that will receive the Dengue vaccine as part of their routine before a travel will be asked to undergo a blood sample at the time of administration of the first dose (T0), 24-48 hours after the first dose (T1) of the vaccine, immediately before the second dose (T2 ) and one to two months after the second dose (T3). Possibly a further sample will be collected within 2 years.",[126],"Dengue Vaccines",[128,129],"Dengue","Vaccine",{"date":107,"type":32},{"date":132,"type":32},"2024-07-10",{"date":134,"type":21},"2028-01",{"name":38,"class":39},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100583206","assessment-of-infection-activity-in-travelers-and-migrants-diagnosed-with-chronic-schistosomiasis-100583206","NCT06873308","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis: a Multicentric Prospective Cohort Study","SchistAct","Inclusion criteria\n\n1. diagnosis of chronic schistosomiasis (\\>3 months after last potential exposure) according to site-specific diagnostic practice\n2. signed informed consent (and assent for minors).\n\nExclusion criteria\n\n1. age below 5 years;\n2. exposure to praziquantel after the last potential exposure to schistosomes\n3. acute infection, i.e. likely infection \\\u003C3 months before presentation","5 Years",{"count":146,"type":21},278,[24],"The primary objective of this clinical investigation is to determine the percentage of travelers and migrants diagnosed with chronic schistosomiasis according to site-specific diagnostic practice who have active infection at the time of evaluation (as assessed and classified by composite reference standards that integrate clinical, laboratory, and diagnostic features, such as microscopy, PCR (where available), POC-CCA (where available), and serum CAA results).\n\nAll subjects with chronic schistosomiasis according to site-specific diagnostic practice will have a standardized baseline clinical and laboratory evaluation at the time of evaluation that will include blood sampling for hematology, schistosome serology available at each site, and schistosome PCR where available; urine sampling for microscopy, determination of hematuria as an indirect marker of morbidity for schistosomiasis, and Schistosome PCR (where available), and urine strip testing POC-CCA (where available); and stool sampling for microscopy and PCR, where available, and fecal occult blood as indirect markers of schistosomiasis morbidity.\n\nComposite reference standards will be used to assess and classify the activity of the infection. Organ-specific ultrasound and other tests will be left to the physician's decision, but results will also be collected.\n\nSerum (at least 1 ml remaining from routine diagnostics) will be sent to LUMC, the Netherlands, where CAA will be determined with the UCP-LF CAA test designed for routine use.\n\nParticipants will be asked to sign an additional consent form, which is optional and not precluding enrollment in the study, to allow the remaining serum to be stored at LUMC for 15 years, to allow secondary research.",[150],"Schistosomiasis",[83,152,153],"chronic","diagnosis","2025-04-16",{"date":156,"type":32},"2025-04-20",{"date":158,"type":32},"2024-06-28",{"date":160,"type":21},"2027-01",{"name":38,"class":39},8,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":40},"100539955","low-and-intermediate-risk-oligometastatic-colorectal-cancer-patients-treated-with-stereotactic-ablative-radiotherapy-100539955","NCT06310564","Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy","A Prospective, Randomized Clinical Trial of Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy: GREEN LaIT-SABR Study","GREENLaIT-SABR","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed CRC\n* Low and intermediate risk oligometastatic colorectal cancer with 1 to 3 metastases, candidate to I or II line systemic treatment (Low risk: 1 to 3 metastases and cumulative tumor volume smaller than 10 cm3; Intermediate risk: 1 to 3 metastases and cumulative tumor volume bigger than 10 cm3).\n* Controlled primary tumor regardless of primary surgery or primary systemic treatment\n* ECOG\u002FWHO 0-2\n* Life expectancy \\> 6 months\n* Lesions ≤ 5 cm\n* Adequate organ function for the planned treatment according to local guidelines\n* For patients with liver metastases: no cirrhosis or hepatitis, and evidence of adequate hepatic function (Total bilirubin level \\\u003C 1.5 x institutional ULN; ALT and AST levels \\\u003C 3.0 x institutional ULN, GGT and alkaline phosphatase levels \\\u003C 3.0 x institutional ULN; INR and APTT levels \\\u003C 1.5 x institutional ULN, Albumin \\> 2.5 mg\u002FdL)\n* For patients with liver metastases: unresectable liver metastases (assessed by a surgeon, preferably hepatobiliary) or refusal of liver surgery before study screening.\n* If childbearing potential, willing to use an effective form of contraception throughout the duration of the study\n* Signed informed consent and willingness to follow the trial procedures\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Brain metastases\n* Having more than 3 metastases\n* Malignant pleural effusion or ascites\n* Unable to undergo imaging by either CT scan or MRI\n* Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance.\n* Pregnancy or breast-feeding",{"count":172,"type":21},204,[24],"This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological Radiotherapy and 18 other Italian centers.\n\nThe reason for this research study is to evaluate whether stereotactic radiotherapy treatment (SABR), in addition to the systemic chemotherapy treatment foreseen by clinical practice for low-intermediate risk oligometastatic colorectal cancer, is able to:\n\n* delay possible local recurrence and\u002For distant polymetastatic progression\n* improve disease-free survival\n* reduce side effects in the short and long term\n\nthus inducing an improvement in the quality of life of patients suffering from this type of pathology.\n\nTherefore, as part of this randomized study, before starting first or second line systemic therapy for his tumor, the patient will be randomized to one of the following treatment arms:\n\n* Experimental arm: ablative stereotactic radiotherapy on all sites of oligometastatic disease (from 1 to 3 sites, performed at most within the second cycle of systemic therapy)\n* Control arm: no ablative stereotactic radiotherapy to sites of oligometastatic disease\n\nThe procedure that is intended to be tested in the experimental arm is a stereotactic radiotherapy treatment on oligometastases (up to a maximum of 3 sites), with ablative dosage (effective biological dose \\>100 Gy), performed before the start of systemic therapy of I or II line (at most within the second cycle of the same).\n\nIt is hoped that the addition of this type of radiotherapy will increase the potential clinical benefit of the treatment in the context of colorectal cancer.",[176],"Colorectal Cancer","2024-11-27",{"date":179,"type":32},"2024-12-02",{"date":181,"type":32},"2024-03-18",{"date":183,"type":21},"2031-04",{"name":38,"class":39},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":193,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":40},"100544878","insights-into-tick-borne-diseases-a-study-from-an-endemic-area-of-northern-italy-100544878","NCT06374615","Insights Into Tick-Borne Diseases: a Study From an Endemic Area of Northern Italy","Insights Into Tick-Borne Diseases: a Prospective Study From an Endemic Area of Northern Italy","TICKTOC","Inclusion Criteria:\n\n* all individuals aged \\> 8 years presenting for tick removal.\n* Individuals providing signed informed consent.\n\nExclusion Criteria:\n\n* tick not available for analysis","8 Years",{"count":195,"type":21},384,[24],"This is a monocentric, experimental, non-pharmacological and non-device no profit study.\n\nThe study is experimental because all the visits and blood withdrawals foreseen by the protocol do not fall within the normal clinical practice.",[199],"Tick-Borne Diseases","2024-04-16",{"date":202,"type":32},"2024-04-18",{"date":204,"type":32},"2024-03-25",{"date":206,"type":21},"2029-03",{"name":38,"class":39},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":40},"100539694","human-leishmaniasis-antigen-recognition-pattern-and-study-of-new-potential-biomarkers-100539694","NCT06307171","Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers","LeishmARPs","CASES:\n\nInclusion criteria:\n\n* Leishmania positive patient from Italy (n=30) and from Sudan (n=30);\n* patient with a clinically or laboratory confirmed diagnosis of leishmaniasis;\n* signed informed consent (criteria not applied in case of samples stored at the Tropica Biobank at the DITM)\n* being clinically classified as leishmaniasis patient by an experienced clinician or being laboratory confirmed as leishmaniasis patients, giving positive to at least two different serological tests or to a molecular test for Leishmania sp.\n* adult subjects (equal or older than 18 years)\n\nExclusion criteria:\n\n* lack of the necessary data and\u002For of biological samples\n* subjects younger than 18 years\n\nCOMMUNITY CONTROLS:\n\nInclusion criteria:\n\n* Cryo-preserved serum samples stored at the Tropica Biobank at the DITM , IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Vr), from subject from Italy (n=30) and from Africa (n=30) with no infection due by Leishmania spp.\n* signed informed consent to Tropica Biobank\n* adult subjects (equal or older than 18 years)\n* being negative to two different serological tests for leishmaniasis\n\nExclusion criteria:\n\n* subjects younger than 18 years\n* being positive to one serological tests for leishmaniasis.\n\nVALIDATION CONTROLS (VC):\n\nInclusion criteria:\n\n* serum samples stored in Tropica Biobank at the DITM from subjects that have been clinically diagnosed with Chagas's disease, or TB, or malaria or leprosy.\n* informed consent signed to Tropical Biobank\n* adult subjects (equal or older than 18 years)\n* being negative to two different serological tests for leishmaniasis.\n* being clinically diagnosed with Chagas disease or TB, or malaria or leprosy\n\nExclusion criteria:\n\n* younger than 18 years\n* positive result to one serological test for leishmaniasis.",{"count":216,"type":21},170,[24],"This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples.\n\nGeneral objectives of the study are: to identify specific biomarkers in order to develop more accurate serological tests for the screening of Leishmania infections that does not present cross-reaction with other infectious diseases; to unveil the Antigen Recognition Patterns (ARPs) of Leishmania infection in humans; to verify whether the ARPs and the new biomarkers are common to different Leishmania infantum strains isolated in Italy as well as in other part of the World and to different strains of L. donovani isolated in Sudan as well as in other part of the World and discard any possible cross reaction with other infectious diseases such as Chagas, TB, leprosy or malaria.",[220],"Leishmaniasis","2024-03-05",{"date":223,"type":32},"2024-03-12",{"date":225,"type":32},"2023-05-22",{"date":227,"type":21},"2026-11",{"name":38,"class":39},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":236,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":40},"100507226","daily-adaptive-radiotherapy-in-postoperative-hypofractionated-salvage-radiotherapy-for-prostate-cancer-patients-100507226","NCT05884632","Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients","DART-PHASER","Inclusion Criteria:\n\n* Age ≤ 80 years;\n* Prostate cancer diagnosis, pT2-3 pN0, any resection margin (R0 or R1);\n* Indication to local salvage treatment defined as: early salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA \\\u003C0.2 ng\u002Fml or salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA ≥0.2 ng\u002Fml;\n* No distant metastases (M0) diagnosed with PSMA-PET-CT;\n* Informed consent to trial's participation and personal data treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old;\n* Adjuvant radiotherapy;\n* Previous radiation in the same anatomical site.","MALE","80 Years",{"count":239,"type":21},184,[24],"This is a monoinstitutional prospective pilot study, aiming to evaluate treatment-related toxicity of an hypofractionated postoperative salvage radiotherapy with daily-adaptive modality in patients affected by prostate cancer biochemical recurrence.\n\nPatients will be treated with postoperative hypofractionated salvage radiotherapy with a dose of 59 Gy in 20 fractions with daily-adaptive modality. Considering the consolidate role and clinical outcome of postoperative hypofractionated radiotherapy with elevate level of evidence (8-10), the study will not be controlled, but compared with literature data.",[243],"Prostate Cancer","2023-05-23",{"date":246,"type":32},"2023-06-01",{"date":248,"type":32},"2023-04-03",{"date":250,"type":21},"2030-04-30",{"name":38,"class":39},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":49,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":101,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":40},"100498477","creation-of-a-bank-of-biological-materials-and-associated-data-related-to-patients-with-infectious-and-tropical-diseases-100498477","NCT05770765","Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases","TropicaBiobank","Inclusion Criteria:\n\n• Informed consent (for healthy volounteers also: age \\> 18 years, health status ascertained by laboratory tests, electrocardiogram and medical examination)\n\nExclusion Criteria:\n\n* History of alcohol\u002Fdrug abuse\n* Pregnant or breastfeeding women, unless there are justified and documented needs",{"count":260,"type":21},60000,"40 Years","This is the protocol that formalizes the establishment of the TROPICA-BIOBANK biobank",[55],"2023-03-14",{"date":266,"type":32},"2023-03-15",{"date":268,"type":32},"2019-10-30",{"date":270,"type":21},"2059-10-30",{"name":38,"class":39},""]